Skip to Main Content

WASHINGTON — Back in 2019, when the Senate Finance Committee called seven drug industry executives to testify, it seemed like proof that Washington was within striking distance of actually reining in the industry’s high prices.

“It’s past time to get beyond the excuses and make prescription drugs affordable,” Sen. Ron Wyden of Oregon, the top Democrat on the committee, told drugmakers that day.


Almost exactly three years later, Wyden will chair another hearing on prescription drug pricing. But this is not a victory lap, nor an opportunity to look at implementation of the sweeping changes Congress has made to this country’s drug pricing system.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.